Blocking the CCR2 protein reduced dermal tightening, lung fibrosis (scarring), and the infiltration of immune cells in the skin in a mouse model of scleroderma, a study shows. The study, “Antifibrogenic effects of C‐C chemokine receptor type 2 antagonist in a bleomycin‐induced scleroderma model,” was…
Horizon Therapeutics announced it plans to pursue the development of HZN-825, a potential therapy for diffuse cutaneous systemic sclerosis (dcSSc) that it gained in acquiring Curzion Pharmaceuticals. Horizon plans to conduct a study this year to investigate the pharmacological profile of HZN-825, previously known as CZN001. Company leaders…
Using vitamin E, pentoxifylline, and the TheraBite Jaw Motion Rehabilitation System may help reduce trismus — commonly called lockjaw — in people with scleroderma, a study in two patients suggests. The research, “Dental management of scleroderma patients using pentoxifylline plus vitamin E with and…
Get regular updates to your inbox.